

Rev03 DATASHEET

Update: Dec,14,2021

FGF-21, His, Human

Cat. No.: Z03207

Product Introduction

Species	Human
Protein Construction	FGF-21 (His29-Ser209) Accession # Q9NSA1 Poly-His
	N-term C-term
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level	$< 0.2 \text{EU}/\mu\text{g}$ of protein by gel clotting method
Biological Activity	$ED_{50}{<}0.3\mu g/ml$, measured in a bioassay using NIH-3T3 cells.
Expression System	СНО
Apparent Molecular Weight	23~25 kDa, on SDS-PAGE under reducing conditions.
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Background

Target Background: FGF-21, also known as fibroblast growth factor-21 and FGFL, is a secreted growth factor belonging to theheparin-binding growth factor family. It is produced by hepatocytes in response to fatty acid stimulation. FGF-21 couples with its co-factor beta-Klotho to signal through FGFR1c and FGFR4. Signal transduction results in insulin-independent uptake of glucose by adipocytes. Clinical administration of FGF-21 induces energy expenditure, fat utilization and lipid excretion.

Synonyms: FGF21; fibroblast growth factor-21; FGFL

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

GenScript USA, Inc.